Abstract
AimsHypomethylating agents (HMAs) exhibit clinical efficacy in patients with myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN). This study was performed to assess residual disease status by flow cytometry immunophenotyping (FCI)...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have